Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Novozymes and Syngenta Enter Global Commercial Agreement

Published: Friday, October 26, 2012
Last Updated: Friday, October 26, 2012
Bookmark and Share
The partners are entering into an exclusive global marketing and distribution agreement on a unique biofungicide used to combat damaging fungal diseases across a range of crops.

Novozymes and Syngenta announced an exclusive global marketing and distribution agreement on the microbial-based biofungicide Taegro®, a natural solution with multiple modes of action used to combat fungal diseases across various crops. The two companies will join forces to bring Novozymes’ Taegro to farmers worldwide through Syngenta’s global organization.

“This collaboration matches Syngenta’s global market strength and leading position within fungicides and integrated solutions with Novozymes’ deep know-how on sustainable, biobased technologies,” says Thomas Videbæk, Executive Vice President of Novozymes. “Using technology developed by Novozymes, Syngenta will provide farmers all over the world with a biological product to help sustainably combat fungal diseases in a powerful manner.”

“We're delighted to enter into another agreement to commercialize a Novozymes technology. Having worldwide commercial rights for Taegro will further strengthen our ability to offer high-performing integrated crop solutions,” comments John Atkin, Chief Operating Officer of Syngenta.

Combatting fungal diseases with sustainable technologies

Taegro offers a biological solution in the form of a microbial-based fungicide, based on the naturally occurring Bacillus subtilis bacterium, which is complementary to existing fungicide technology. It effectively targets fungal diseases such as Rhizoctonia and Fusarium on fruit and vegetables, and its application is expected to be expanded to a wider portfolio of broad-acre crops such as wheat, soy and corn.

Companies to share task of bringing technology to market

Under the terms of the agreement, Novozymes and Syngenta will share the task of bringing Taegro to market. Syngenta will be responsible for sales, marketing and distribution, while Novozymes will be responsible for production and registration. Trials are planned to secure data to continue to build on the current U.S. registration in other regions, following which the two companies aim for a global rollout.

Financial details about the agreement are not being disclosed.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Adisseo,Novozymes Enter Partnership in Probiotics for Animals
The companies will develop a product based on naturally occurring microbes that can reduce antibiotic usage in poultry and brings associated health benefits.
Monday, June 01, 2015
Novozymes, Cargill Continue Bio-Acrylic Acid Partnership as BASF Exits
Novozymes and Cargill remain committed to bringing technology to market.
Wednesday, January 28, 2015
Novozymes, Monsanto Showcase Innovations Expected to Increase Farm Sustainability
Companies’ BioAg Alliance working to develop innovations for agriculture to boost productivity.
Thursday, August 28, 2014
Novozymes and Monsanto Partner
Companies establish The BioAg Alliance to discover, develop and sell microbial solutions which enable farmers to increase crop yields with less input.
Tuesday, December 17, 2013
Novozymes and Raízen to Collaborate on Cellulosic Ethanol
Novozymes will supply enzyme technology to Raízen’s first commercial-scale cellulosic ethanol plant in Brazil.
Friday, September 20, 2013
Europe to Invest €3.8 Billion in the Biobased Economy
48 Companies join forces with the European Commission to set up a Public-Private Partnership and accelerate the deployment of biobased products in Europe.
Monday, July 15, 2013
Novozymes Biopharma Helps Innovative Dry Eye Therapy Move into Clinical Trials
A novel ophthalmic solution has recently obtained FDA approval to undergo Phase I/II clinical trials in the United States.
Monday, May 20, 2013
Novozymes' New CEO Takes Office
Peder Holk Nielsen takes over from Steen Riisgaard in a planned transition, vows to bring more innovation to the market faster.
Tuesday, April 02, 2013
Novozymes Acquires Enzyme Business from Iogen Corporation
The acquisition complements Novozymes’ existing business in the pulp & paper, textile, grain-processing and animal feed industries.
Monday, February 04, 2013
Novozymes and Syngenta to partner in delivering JumpStart® — For enhanced phosphate fertility within bioagriculture
The agreement provides an exclusive expansion into new markets for JumpStart, which is a biological that enhances phosphate fertility in agriculture, offering growers an integrated and sustainable seed care solution
Friday, May 11, 2012
Shengquan and Novozymes in partnership to commercialize cellulosic ethanol
The Chinese Shengquan Group will start commercial production of cellulosic ethanol for solvents and biochemicals in June 2012 utilizing enabling technology from Novozymes
Friday, May 11, 2012
Novozymes reaches 2011 financial targets; cautious 2012 outlook
Novozymes, the world leader in bioinnovation and industrial enzymes, today reported satisfactory 2011 results in line with expectations.
Tuesday, January 24, 2012
Novozymes Biopharma to Present Latest Research on Recombinant Human Albumin at AAPS
Recombinant human albumin as a multifunctional excipient for the stabilisation of therapeutic protein formulations. Study results to be presented at the 2011 AAPS National Biotechnology Conference.
Wednesday, March 23, 2011
Novozymes Announces Master File for Recombinant Albumin
The dossier, containing information on the manufacture and safety of albucult, can help support the medical devices and drug formulation applications.
Friday, September 03, 2010
Novozymes Showcases Biopharmaceutical Solutions at BioProcess International 2010
The Company plans to feature its range of regulatory compliant, recombinant and animal-free products and technologies at the annual conference.
Friday, September 03, 2010
Scientific News
13 Ways to Stop an Unseen Force from Disrupting Weighing
Download a free Mettler Toledo paper to discover how to halt static’s negative effects before the next weigh-in.
Flinders Ig Nobel Winner Cracks Global Anaesthetic
One of the world’s most in-demand anaesthetics can now be produced on the spot, thanks to the thermos-flask sized device that recently won Flinders University inventor Professor Colin Raston an Ig Nobel prize.
Resurrected Proteins Double Their Natural Activity
Researchers demonstrate method for reviving denatured proteins.
Genes That Protect African Children From Developing Malaria Identified
Variations in DNA at a specific location on the genome that protect African children from developing severe malaria, in some cases nearly halving a child’s chance of developing the life-threatening disease, have been identified in the largest genetic association study of malaria to date.
Messing With The Monsoon
Manmade aerosols can alter rainfall in the world’s most populous region.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Scientists Decode Structure at Root of Muscular Disease
Researchers at Rice University and Baylor College of Medicine have unlocked the structural details of a protein seen as key to treating a neuromuscular disease.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
New Test Detects All Viruses
A new test detects virtually any virus that infects people and animals, according to research at Washington University School of Medicine in St. Louis, where the technology was developed.
Inroads Against Leukemia
Potential for halting disease in molecule isolated from sea sponges.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos